Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease

Francesco Caso, Donato Rigante, Antonio Vitale, Luisa Costa, Vittoria Bascherini, Eugenia Latronico, Rossella Franceschini, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

13 Citazioni (Scopus)


Vogt-Koyanagi-Harada disease (VKHD) is a multisystemic disorder characterized by granulomatous panuveitis variably combined with T cell-mediated neurologic and cutaneous manifestations. Early and aggressive treatment with systemic corticosteroids is the mainstay of treatment for VKHD. Additional use of immunosuppressants, intravenous immunoglobulins, and tumor necrosis factor-alpha inhibitors can help the most severely affected patients and work as corticosteroid-sparing agents. We report the case of a young woman with relapsing and multiresistant VKHD who demonstrated a stable remission of both uveitis and high-frequency hearing loss following rituximab intravenous administration (1 g. twice, 2 weeks apart, and 6 months later). A complete clinical response was observed 1 month since the first infusion, and no ocular relapses were recorded during the following year; in addition, audiometry showed a high-frequency hearing recovery in the right ear. Further observational studies are required to define the role of CD20 inhibition in the management of VKHD.
Lingua originaleEnglish
pagine (da-a)1817-1820
Numero di pagine4
RivistaClinical Rheumatology
Stato di pubblicazionePubblicato - 2015


  • Vogt-Koyanagi-Harada disease


Entra nei temi di ricerca di 'Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease'. Insieme formano una fingerprint unica.

Cita questo